Table 1 Demographic, clinical, and serological features, according to ESSG index[8],[9]
Whole cohort | Patients with lcSSc | Patients with dcSSc | |
|---|---|---|---|
Patients (F/M) | 107 (97 F, 10 M) | 57 (53 F, 4 M) | 50 (44 F, 6 M) |
Mean age (range) (yrs.)1 | 55.8 (18-84) | 58.1 (28-84) | 53.3 (18-84) |
Mean disease duration (range) (yrs.) | 6.1 (0.5-30) | 7.4 (0.5-30) | 4.8 (0.5-20) |
ESSG index ≥3.5 (no. of pts.)2 (%) | 32 (29.9%) | 18 (16.8%) | 14 (13.1%) |
Mean mRSS (range) (yrs.) | 3.1 (0-32) | 2.4 (0-5) | 3.5 (0-32) |
Scleredema (no. of pts.) (%) | 60 (56.1%) | 32 (56.1%) | 28 (56.0%) |
Δ3Skin involvement (no. of pts.) (%) | 18 (16.8%) | 11 (19.2%) | 7 (14.0%) |
Ulcers (no. of pts.) (%) | 22 (21.5%) | 11 (19.2%) | 11 (22.0%) |
Δ1Vascular features (no. of pts.) (%) | 25 (23.4%) | 14 (24.5%) | 11 (22%) |
Arthritis (no. of pts.) (%) | 5 (4.7%) | 3 (5.2%) | 2 (4%) |
DLCO <80%4 (no. of pts.) (%) | 67 (63.2%) | 35 (61.4%) | 32 (64.0%) |
Δ1Cardiopulmonary features (no. of pts.) (%) | 20 (18.7%) | 10 (17.5%) | 10 (20.0%) |
ESR >30 mm/h (no. of pts.) (%) | 32 (29.9%) | 14 (24.5%) | 18 (36.0%) |
Hypocomplementemia (no. of pts.) (%) | 12 (11.7%) | 9 (15.7%) | 3 (6.0%) |